ASTH Valuation
Astrana Health Inc
$
27.180
- Overview
- Forecast
- Valuation
ASTH Relative Valuation
ASTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASTH is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for ASTH's competitors is 1.25, providing a benchmark for relative valuation. Astrana Health Inc Corp (ASTH) exhibits a P/S ratio of 0.49, which is -61.02% above the industry average. Given its robust revenue growth of 53.43%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
BEAM
Beam Therapeutics Inc
17.890
USD
+3.71%
FL
Foot Locker Inc
23.850
USD
-0.21%
COCO
Vita Coco Company Inc
35.620
USD
+2.92%
HLMN
Hillman Solutions Corp
8.060
USD
-0.49%
OMCL
Omnicell Inc
27.960
USD
-0.43%
VITL
Vital Farms Inc
35.800
USD
+4.53%
LION
Lionsgate Studios Corp
6.820
USD
+0.59%
DBRG
DigitalBridge Group Inc
11.950
USD
+1.01%
TALO
Talos Energy Inc
8.290
USD
-1.54%
TGS
Transportadora de Gas del Sur SA
30.710
USD
-2.01%
FAQ
Is Astrana Health Inc (ASTH) currently overvalued or undervalued?
Astrana Health Inc (ASTH) is now in the Fair zone, suggesting that its current forward PE ratio of 19.83 is considered Fairly compared with the five-year average of 37.07. The fair price of Astrana Health Inc (ASTH) is between 24.82 to 66.94 according to relative valuation methord.
What is Astrana Health Inc (ASTH) fair value?
How does ASTH's valuation metrics compare to the industry average?
What is the current P/B ratio for Astrana Health Inc (ASTH) as of May 19 2025?
What is the current FCF Yield for Astrana Health Inc (ASTH) as of May 19 2025?
What is the current Forward P/E ratio for Astrana Health Inc (ASTH) as of May 19 2025?